Valuation: Aradigm Corporation

Market Cap 4.89M 4.34M 4.06M 3.7M 6.96M 470M 7.06M 49.09M 19M 240M 18.34M 17.94M 769M P/E 2016
-0.72x
P/E 2017 -9.3x
Enterprise Value 12.8M 11.37M 10.63M 9.69M 18.24M 1.23B 18.49M 129M 49.78M 628M 48.05M 47.01M 2.02B EV / Sales 2016
73.3x
EV / Sales 2017 7.27x
Free-Float
60.28%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+6.73% - - 702K
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.86%-1.28%+24.76%+78.67% 59.26B
+1.05%-0.39%+4.54%+34.84% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.44%+0.20%+52.90%+154.17% 39.24B
Weighted average by Cap. +0.06%-0.32%+58.09%+145.87%

Financials

2016 2017
Net sales 195K 173K 162K 148K 278K 18.77M 282K 1.96M 759K 9.56M 732K 716K 30.71M 14.46M 12.85M 12.01M 10.95M 20.61M 1.39B 20.9M 145M 56.27M 709M 54.31M 53.13M 2.28B
Net income -32.94M -29.26M -27.36M -24.93M -46.94M -3.17B -47.58M -331M -128M -1.62B -124M -121M -5.19B -10.7M -9.51M -8.89M -8.1M -15.25M -1.03B -15.46M -108M -41.64M -525M -40.19M -39.32M -1.69B
Net Debt -9.37M -8.32M -7.78M -7.09M -13.36M -902M -13.54M -94.17M -36.46M -460M -35.19M -34.42M -1.48B 7.91M 7.03M 6.57M 5.99M 11.28M 762M 11.43M 79.51M 30.78M 388M 29.71M 29.07M 1.25B
Logo Aradigm Corporation
Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
Employees
-
  1. Stock Market
  2. Stocks
  3. ARDMQ Stock